Last reviewed 2026-06-01 · How we verify

Turloc (METUREDEPA)

Phase 2 active Small molecule ✓ Verified Jun 2026

Turloc (generic name: METUREDEPA) is a meturedepa drug. It is currently in Phase 2 development.

Turloc works by interacting with a specific molecular target to produce a therapeutic effect.

Turloc (METUREDEPA) is a small molecule drug in the meturedepa class, but information on its target, approved indications, and commercial status is limited. As a pharma professional, it is essential to note that Turloc's development history, pharmacokinetic properties, and safety profile are not well-documented. Further research is necessary to understand Turloc's mechanism of action and potential therapeutic applications. The lack of information on Turloc's target and approved indications suggests that it may be an investigational or experimental compound. More data is required to assess its clinical utility and safety profile.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	METUREDEPA
Drug class	meturedepa
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Turloc has a key that fits into those locks. When Turloc binds to its target, it helps to regulate the activity of the cells, which can lead to various therapeutic benefits. However, the exact mechanism of action and how Turloc interacts with its target are not well-understood at this time.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Turloc CI brief — competitive landscape report
Turloc updates RSS · CI watch RSS

Frequently asked questions about Turloc

What is Turloc?

Turloc (METUREDEPA) is a meturedepa drug.

How does Turloc work?

Turloc works by interacting with a specific molecular target to produce a therapeutic effect.

What is the generic name of Turloc?

METUREDEPA is the generic (nonproprietary) name of Turloc.

What drug class is Turloc in?

Turloc belongs to the meturedepa class. See all meturedepa drugs at /class/meturedepa.

What development phase is Turloc in?

Turloc is in Phase 2.

Drug class: All meturedepa drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing